Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia
OwnerWalter Howard Peschelinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions and treatment regimes useful in treating one or more of the following conditions: inflammation, kidney disease, eye disease, end-organ injury, systemic endotoxemia, and/or vitamin D resistance. The compositions and treatment regimes are also useful in reducing elevated CRP levels and/or elevated pro-inflammatory cytokines.
Claims30
1-55. (canceled)
A pharmaceutical composition comprising a fibrate anti-hyperlipidemic agent, a MG-CoA reductase inhibitor, an aldosterone antagonist and a pharmaceutically acceptable carrier.
A pharmaceutical treatment regime for reducing inflammation and/or systemic endotoxemia in a subject, the regime comprising administering to a subject at least the following pharmacologically active ingredients within a 24 hour period:
- a fibrate anti-hyperlipidemic agent, a MG-CoA reductase inhibitor, an aldosterone antagonist, and optionally, a pharmaceutically acceptable carrier, wherein the pharmacologically active ingredients are in an amount sufficient to reduce inflammation and/or endotoxemia in the subject.
A pharmaceutical treatment regime for lowering the C-reactive protein (CRP) level in a human patient's blood, the regime comprising administering to a subject at least the following pharmacologically active ingredients within a 24 hour period:
- a fibrate anti-hyperlipidemic agent, a MG-CoA reductase inhibitor, an aldosterone antagonist, and optionally a pharmaceutically acceptable carrier, wherein the pharmacologically active ingredients are in an amount sufficient to lower the C-reactive protein (CRP) level in the patient's blood.
A kit comprising an effective amount of the following pharmacologically active ingredients:
- a fibrate anti-hyperlipidemic agent, a MG-CoA reductase inhibitor, an aldosterone antagonist and optionally a pharmaceutically acceptable carrier and instructions describing the pharmaceutical treatment regime of claim 12.
Dependencies are inferred from the claim text.